FP-045
Fanconi Anemia
Phase 2Active
Key Facts
About Foresee Pharmaceuticals
Foresee Pharmaceuticals is a purpose-driven, clinical-stage biopharma focused on improving patient quality of life through innovative drug delivery and novel therapeutics. Its core strategy is built on two pillars: a proprietary Stabilized Injectable Formulation (SIF) platform for creating long-acting injectables that enhance compliance, and a pipeline of first/best-in-class New Chemical Entities (NCEs) for severe, underserved diseases. Key achievements include advancing multiple programs into late-stage clinical trials, such as FP-045 for Fanconi Anemia and its SIF-based Leuprolide for Central Precocious Puberty, while establishing a global partnership strategy to commercialize its products worldwide.
View full company profileTherapeutic Areas
Other Fanconi Anemia Drugs
| Drug | Company | Phase |
|---|---|---|
| MV Platform for Rare Disease | STRM.BIO | Preclinical |